Anytime I find high-growth companies trading below the market’s average price-to-earnings (P/E ) ratio, I have to pinch myself. #-ad_banner-#After all, how often can you buy strong growth at a discount to the market — and get paid a dividend in the bargain? And at prices near $10, you can buy enough shares to make a strong impact on your portfolio. But before I get too excited, I need to verify the investment thesis by answering a few questions… Is the growth sustainable? How strong is the balance sheet? Does the market price make sense? Let’s take three… Read More

Anytime I find high-growth companies trading below the market’s average price-to-earnings (P/E ) ratio, I have to pinch myself. #-ad_banner-#After all, how often can you buy strong growth at a discount to the market — and get paid a dividend in the bargain? And at prices near $10, you can buy enough shares to make a strong impact on your portfolio. But before I get too excited, I need to verify the investment thesis by answering a few questions… Is the growth sustainable? How strong is the balance sheet? Does the market price make sense? Let’s take three stocks I’ve been following. All three have cheaper valuations than the S&P 500, with high projected growth and dividend yields greater than 4%. Each also has a market cap greater than $1 billion; stocks with larger market caps usually have more trading volume,   which typically makes them easier to buy and sell. Are these three worth buying? Let’s take a closer look. PDL Biopharma (Nasdaq: PDLI ) PDL Biopharma is a biotech company that develops drugs for cancer and immunologic diseases. Read More